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The product of the putative proto-oncogene bcl-3 is an IKcB-like molecule with novel binding properties
specific for a subset of the rel family of transcriptional regulators. In vitro, Bcl-3 protein specifically inhibited
the DNA binding of both the homodimeric NF-KcB p5O subunit and a closely related homolog, p52 (previously
p49), to immunoglobulin K NF-cB DNA motifs. Bcl-3 could catalyze the removal of these proteins from DNA.
At concentrations that significantly inhibited DNA binding by homodimeric p5O, Bcl-3 did not inhibit binding
of reconstituted heterodimeric NF-KB (p5O:p65), a DNA-binding homodimeric form of p65, or homodimers of
c-Rel. Phosphatase treatment of Bcl-3 partially inactivated its inhibitory properties, implicating a role for
phosphorylation in the regulation of Bcl-3 activity. Bcl-3, like p5O, localizes to the cell nucleus. In cells
cotransduced with Bcl-3 and p5O, both molecules could be found in the nucleus of the same cells. Interestingly,
coexpression of Bcl-3 with a p50 mutant deleted for its nuclear-localizing signal resulted in the relocalization
of Bcl-3 to the cytoplasm, showing that the proteins interact in the cell. These properties contrast Bcl-3 to
classically defined IKB, which maintains heterodimeric NF-cB p5O:p65 in the cytoplasm through specific
interactions with the p65 subunit. Bcl-3 appears to be a nuclear, IKB-related molecule that regulates the activity
of homodimeric nuclear p5O and its homolog p52.
IKB is a physiologic controller of the activity of the NF-irB
transcription factor (2, 3, 13). It is found in the cytoplasm of
cells complexed with NF-KB, a heterodimer of the Rel-
related proteins p5O and p65. IKB interacts with NF-KB
through residues in the Rel homology domain of the p65
subunit of NF-KB (31). Upon stimulation of cells with a
variety of agents, IKB dissociates from the complex and
NF-KB translocates to the nucleus, where it directs the
expression of a number of genes, including immunoglobulin
K (IgK) (34), interleukin-6 (25), tumor necrosis factor alpha,
beta interferon (24), and human immunodeficiency virus (28)
genes. Two species of IKB have been described: IKB-a (36
kDa) and IKB-3 (45 kDa) (45). Cloned mammalian IKB-a, a
product of the Mad-3 gene (17), and pp4O, the avian IKB-like
inhibitor of c-Rel activity (15), contain a repeated 33- to
35-amino-acid residue motif termed an ankyrin domain.
Ankyrin domains are also found in NF-KB p50 precursor
p105 (14, 23) as well as in other proteins such as Bcl-3 (32),
CDC10 (1), SWI4/SWI6 (6), the Drosophila Notch-related
proteins (Xotch, Rotch, Tan-1, and Int-3 [6, 8, 10, 41, 42]),
Lin-12, Glp-1 (44), and erythrocyte ankyrin (27).
Two different classes of ankyrin-containing rel-binding
proteins have been characterized previously. The first, a
product of the cDNA clone AMD-3, encodes the a isoform
of IKB (45), as defined by amino acid analysis (9). IKB-a
binds specifically to the p65 subunit of NF-KB (17, 31, 39)
and is the apparent murine homolog of pp4O, the associated
phosphoprotein of c-Rel (15). The second ankyrin-containing
protein, IKB--y, preferably inhibits the DNA binding of p5O
homodimers (19, 26). p5O derives from the p105 precursor by
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cleavage, and IKB--y is the protein product of an alternatively
spliced mRNA arising from the p105 locus, corresponding to
the carboxy-terminal half of p105. As part of p105, IKB--y
appears to participate in internal inhibition of the rel domain
in p105 as well as in masking of the nuclear translocation
signal of p105 (5, 18).
We noted that the predicted ankyrin domains of the
previously cloned proto-oncogene bcl-3 can be aligned with
greater significance to IKB-like molecules than with ankyrin-
containing molecules having no known IKB function (30).
bcl-3 has been described as a putative proto-oncogene found
at a 14:19 translocation breakpoint in the IgH-a region (32) in
a small number of adult chronic lymphocytic leukemias,
neoplasms of the CD5+ B-cell subset (36). An interesting
feature of Bcl-3 is the high density of serine and proline
residues present at the carboxyl terminus of the molecule.
The normal cellular functions of bcl-3 and its role in leuke-
mogenesis remain to be determined.
We find that baculovirus-produced Bcl-3 specifically in-
hibits the DNA binding of homodimeric p5O and its close
homolog p52. Surprisingly, Bcl-3, at concentrations that
inhibited >90% of p5O homodimeric complexes, did not
efficiently inhibit the DNA binding of heterodimeric Rel
complexes that contain p5O, such as reconstituted p5O:p65.
This is in contrast to the activity of IKB-a, which is capable
of inhibiting both homodimers and heterodimers of com-
plexes containing c-Rel and p65. In contrast to the proposed
role of IKB as a regulator of cytoplasmic-nuclear partitioning
for NF-KB, we found that Bcl-3 is an intrinsically nuclear
protein that associates with p50 in vivo. Thus, it is possible
that Bcl-3 plays a broader role as a regulator of p5O tran-
scriptional activity. While this report was in preparation,
Wulczyn et al. (43) reported evidence on the properties of
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Bcl-3, some of which are consistent and others of which are
in contrast to those presented here (see Discussion).
MATERIALS AND METHODS
Proteins. SF9 cells were grown in Grace's medium sup-
plemented with 10% fetal calf serum. p50, p65, and p65-
Acarboxyl were made in a baculovirus expression system
and purified according to Fujita et al. (12). NF-KB pSO:p65
was prepared similarly. p52 was a kind gift of Colin Duckett
and Gary Nabel (33). c-Rel was prepared in a baculovirus
expression system and purified similarly to the Rel-related
proteins (12). Bcl-3 was made by a baculovirus expression
system and was purified by standard column chromatogra-
phy (T. Fujita) to near homogeneity. IKB-a was fused after
the initiating ATG to glutathione synthetase (GST) and
purified by glutathione agarose affinity chromatography (26).
The Drosophila proteins cactus and notch, also glutathione
S-transferase (GST) fusions, were a kind gift of Simon Kidd;
Cactus protein was previously shown to be functional in the
inhibition of Dorsal protein binding to dorsal DNA-binding
sites (22b). Rabbit polyclonal antibody to the baculovirus-
derived p50 and Bcl-3 purified in this study was prepared and
used as described in the text.
Immunofluorescence. NIH 3T3 cells seeded onto glass
coverslips were infected with retroviruses produced by a
transient-transfection protocol (32a). A bc13 cDNA was
inserted into the NcoI site of the defective retrovirus con-
struct MFG (a kind gift from P. Robbins, University of
Pittsburgh, and R. Mulligan, Whitehead Institute) by using
synthesized linkers corresponding to the DNA sequence
from the second residue to the unique XmaI site in bcl-3. At
the 3' end, bcl-3 was fused to the BamHI site of MFG, using
the first BstYI site 3' of the bcl-3 terminator codon (in the
case of native bcl-3); the resulting construct was designated
MFG-bcl-3. An influenza virus hemagglutinin (HA) epitope
tag was added to Bcl-3 by using a synthesized linker corre-
sponding to sequence from the unique RsaI site of bcl-3 to
the last codon that included a fused HA epitope, a new
terminator, and a BamHI site; the resulting construct was
designated MFG-bcl-3-HA. Two days postinfection cells,
were stained according to Van Etten et al. (40) in a two-step
procedure; the primary antibody was monoclonal anti-HA
epitope antibody 12CA5 (Berkeley Antibody Co., Berkeley,
Calif.), and the secondary antibody was a rhodamine-conju-
gated donkey Fab2 anti-mouse IgG. p50 tagged at the amino
terminus with HA epitope was inserted in the pZip-
NeoSV(X)-1 retrovirus (7), using the XhoI and blunted ClaI
sites (thus removing the neo, pBR origin of replication, and
simian virus 40 origin of replication sequences); the resulting
construct was designated pZip-HA-p5O. A retrovirus direct-
ing the expression of wild-type p50 was derived from pZip-
HA-pSO by replacing the Rel region with the wild-type NcoI
fragment containing all of the Rel homology region and some
regions carboxy terminal to it; the resulting construct was
designated pZip-p50. A retrovirus directing the expression of
a nuclear-localizing mutant of p50, designated pZip-p50-
ANLS, was constructed similarly from a p50 construct
deleted of residues 351 to 367. A polyclonal antibody to
Bcl-3 from immunized rabbits was used at a 1:300 dilution in
immunofluorescence staining of cells infected with MFG-
bcl-3. Polyclonal fluorescein isothiocyanate-labeled donkey
anti-rabbit IgG was used at 1:250 to reveal Bcl-3 overexpres-
sion in NIH 3T3 cells.
EMSA and phosphatase treatment. Approximately 1 ng of
each Rel protein was mixed with the indicated ankyrin
motif-containing protein and incubated for 5 min at room
temperature prior to the addition of radiolabeled probe. All
buffers were as described previously (2). After incubation for
an additional 5 min, the samples were analyzed by EMSA
(2). For phosphatase treatment experiments, Bcl-3 was
incubated with an equivalent amount of calf intestine phos-
phatase (CIP). A portion was subjected to denaturing sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE). The rest was diluted for use in assay of inhibitory
effect on p5O DNA binding. Destruction of Bcl-3 protein by
proteolytic contaminants of the CIP was not observed.
Western immunoblotting and immunoprecipitation. Cells
infected with retroviruses (32a) directing the expression of
HA-tagged Bcl-3 were homogenized in sample buffer (1%
SDS, 50 ,uM 3-mercaptoethanol, 0.2% bromophenol blue),
and insoluble material was removed by centrifugation. Pro-
teins were electrophoresed through SDS-12.5% polyacryl-
amide gels, and proteins were electrotransferred to a nitro-
cellulose support. Immunoblots were blocked with 5%
nonfat milk antibody proteins. Primary antibody was protein
A-purified monoclonal 12CA5 (anti-HA; Berkeley Antibody
Co.) at a 1:1,000 dilution. Bands were revealed with protein
A-alkaline phosphatase conjugate at 1:5,000. For immuno-
precipitations, 293 cells that were transfected by calcium
phosphate precipitation of DNA were labeled for 6 h with
500 ,uCi of [35S]methionine. Cells were lysed in immunopre-
cipitation buffer (20 mM Tris [pH 8.0], 137 mM NaCl, 1%
Nonidet P-40, 10% glycerol, and 2 mM EDTA, with the
protease inhibitors aprotinin, benzamidine, phenylmethyl-
sulfonyl fluoride, antipain, and tosylsulfonyl phenylalanyl
chloromethyl ketone). Cells were vigorously vortexed and
then briefly sonicated; insoluble material was removed by
centrifugation. Then 2 x 106 incorporated counts were
diluted into 1 ml of immunoprecipitation buffer and pre-
cleared with Sepharose-protein A beads for 1 h. Primary
antibodies (both polyclonal anti-p5O and polyclonal anti-
Bcl-3) at 1:500 were added and allowed to incubate overnight
at 4°C with rocking. Protein A beads (precoated with cold
293 cell lysate) were added for 1 h. Beads were washed five
times in immunoprecipitation buffer. Sample buffer was
added to washed beads and heated to 100°C briefly, and
proteins were visualized by autoradiography after SDS-
PAGE separation.
RESULTS
Bcl-3 is an IKB-like inhibitor of (P50)2 binding to IgK NF-KB
DNA motifs. To examine the ability of Bcl-3 to inhibit the
DNA-binding activity of Rel-related proteins, we produced
recombinant full-length murine Bcl-3 protein by using a
baculovirus expression system, purified it to near homoge-
neity and tested its activity in an EMSA. We first tested the
inhibitory properties of Bcl-3 on the DNA-binding properties
of homodimers of p50 and heterodimeric pSO:p65 NF-KB
(Fig. 1A). Titration of increasing amounts of baculovirus
Bcl-3 resulted in the inhibition of (P5O)2 binding to the IgK KB
DNA motif and had no apparent inhibitory effect upon
reconstituted NF-KB binding. The molar ratio that gave 90%
inhibition of (P5o)2 binding to IgK motifs was approximately
5 Bcl-3:1 (P5O)2-
We next tested the specificity of the Bcl-3 inhibitory effect
upon other homo- and heterodimeric cloned Rel homologs:
murine p50 (12, 14), a DNA-binding truncated form of
murine p65 (12, 31), c-Rel (15), and the 52-kDa derivative of
human lyt-10/plOO (p52; previously designated p49) (29, 33).
Five nanograms of Bcl-3 inhibited the binding of 1 ng of p5O
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FIG. 1. Evidence that Bcl-3 preferentially inhibits the DNA binding of NF-aB p5O and NF-KB p52. A radiolabeled oligonucleotide probe
containing the NF-KB motif from the IgK intronic enhancer was used in EMSA with the indicated amounts of Rel-related DNA-binding
proteins and the indicated amounts of ankyrin motif-containing proteins. Ankyrin proteins were premixed, except where indicated, with Rel
proteins, allowed to incubate, and then added to radiolabeled probe. (A) Twofold serial dilutions from 0.2 to 25 ng to determine the amount
(molar ratio) of Bcl-3 protein that inhibits 5 ng of (p50)2 versus the amount of Bcl-3 that inhibits NF-KB p5O:p65. (B) Test of ankyrin protein
inhibitory activities upon other Rel complexes. Inhibition trials were carried out with either approximately 5 ng of Bcl-3, 5 ng of GST-IKB-oc,
100 ng of GST-cactus, 100 ng of GST-notch, or 5 ng of Bcl-3 boiled for 10 min. Proteins added are as indicated above the lanes; all Rel-related
proteins were added to approximately 1 ng. (C) Test for active inhibition by Bcl-3 of p5O DNA binding. Lanes: 1, p5O plus IgK site; 2, p5O
plus IgK KB site premixed for 20 min, with subsequent addition of Bcl-3; 3, p5O and Bcl-3 premixed for 20 min, with subsequent addition of
the IgK KB DNA-binding motif. Reactions were then immediately electrophoresed in EMSA.
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or p52 homodimers to DNA (Fig. 1B, lanes 2 and 20) but did
not significantly inhibit the specific DNA binding of 1 ng of
homodimers of p65-A(BspHI) (lane 14) or c-Rel (lane 23), nor
did it inhibit the DNA binding of the reconstituted NF-KB
heterodimer pSO:p65 under these conditions (lane 8). The
response to Bcl-3 was complementary to the activity of
IKB-a. Consistent with previous reports (9, 15, 17), 2 ng of
IKB-a inhibited the binding of all heterodimeric and ho-
modimeric complexes containing p65 or c-Rel (lanes 9, 15,
and 24) but did not influence p50 or p52 homodimers to a
significant degree (lanes 3 and 21). Although c-Rel ho-
modimer binding to IgK sites is reproducibly and character-
istically less efficient than the binding of NF-KB and p50
homodimers, the specificity of its inhibition by lKB-a and not
by Bcl-3 is clear. Other ankyrin repeat-containing proteins
such as Cactus, the genetically defined controller of the
Drosophila axis-determining gene dorsal, or Notch protein
did not affect the DNA-binding capacity of any of the
mammalian Rel-related proteins (lanes 4, 5, 10, 11, 16, and
17). Thus, there is specificity in the ankyrin motif-mediated
interactions of both Bcl-3 with p50 or p52 and IKB-cx with p65
or c-Rel (Fig. 1B and unpublished data).
Zabel and Baeuerle (45) showed that IKB-ao can actively
dissociate a complex of NF-KB and DNA. Because p50
binding to various KB sites on DNA has a half-life of greater
than 1 h, we investigated whether Bcl-3 could actively
dissociate the complex by varying the order of addition of
the components in the reaction. When Bcl-3 protein was
added either before or after the (p50)2-DNA complex was
formed and the complexes were rapidly submitted to elec-
trophoretic separation, Bcl-3 equally efficiently inhibited
(P5o)2 interaction with the IgK KB site (Fig. 1C, lanes 2 and
3). Thus, a common property of Bcl-3 and IKB is that both
can actively dissociate from DNA their cognate Rel-like
protein targets, (P5o)2 and NF-KB, respectively.
Bcl-3 requires phosphorylation to efficiently inhibit P(50)2.
Because Bcl-3 has a string of serine residues just carboxy
terminal to the ankyrin repeats, we tested whether Bcl-3 was
a phosphoprotein and whether phosphorylation of Bcl-3
might play a role in its inhibitory activity. Purified Bcl-3
produced in insect cells migrated as a single broad band in
SDS-PAGE (Fig. 2A, lane 1) at an apparent molecular size of
52 kDa, as visualized by Coomassie blue staining. Multiple
isoforms, migrating at approximately 52 kDa, were also
visible in a Western blot of mammalian cells expressing
retrovirus transduced epitope-tagged Bcl-3 (Fig. 2B, lane 2).
The predicted size of Bcl-3 from its DNA sequence is 46
kDa. CIP treatment (Fig. 2A, lane 2) resulted in a reduction
in size of baculovirus-produced Bcl-3, suggesting that its
large apparent size and heterogeneity were at least in part
due to phosphorylation. Importantly, dephosphorylated
Bcl-3 was less efficient at inhibiting binding of p50 to KB sites
(Fig. 2C, lanes 5 to 7). Control lanes with Bcl-3 alone or
CIP-treated p50 do not exhibit this effect, suggesting that
phosphorylation is necessary for Bcl-3 to efficiently inhibit
p50 binding to IgK KB motifs. By contrast, when dephosphor-
ylated, IKB-ao inhibits the DNA-binding activity of NF-KB
(22, 45) through specific interaction with the p65 subunit
(31). Only IKB-, has been previously shown to require
phosphorylation (22). Thus, Bcl-3, which has several poten-
tial protein kinase C and creatine kinase II phosphorylation
sites predicted from its sequence (32), might also require
phosphorylation to be active. Phosphorylation could ac-
count for the aberrant migration and multiple isoforms
observed.
Bcl-3 associates with p50 and localizes to the nucleus. To
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FIG. 2. Evidence that phosphorylation regulates the inhibitory
activity of Bcl-3. (A) Bcl-3 protein was mixed with equivalent
amounts of CIP as indicated. The arrows indicate the apparent sizes
(in kilodaltons) of baculovirus Bcl-3 prior to and after CIP treat-
ment. Proteins were visualized by Coomassie blue staining. (B) NIH
3T3 cells were transfected with a mixture of the full-length helper
virus murine leukemia virus (MuLV) in pZAP (35) and the MFG
retrovirus containing full-length influenza virus (flu) epitope-tagged
murine bcl-3, as indicated. Two days later, supernatants containing
helper and bcl-3 viruses were harvested and used to infect fresh NIH
3T3 cells (7). After 48 h, cells were harvested, lysed, and subjected
to SDS-PAGE. Western blot analysis of transferred proteins was
carried out with the monoclonal antibody to the influenza virus HA
epitope. Multiple bands are visible and are indicated by arrows. (C)
Phosphatase-treated Bcl-3 prepared as for panel B was used in
EMSA (see Fig. 2) to test the role of phosphorylation in the activity
of Bcl-3. Lanes: 1, 32P-radiolabeled IgK DNA motif alone; 2, Bcl-3;
3, CIP; 4, CIP-treated Bcl-3; 5, p50; 6, p50 plus Bcl-3; 7, CIP-treated
Bcl-3 plus p5O; 8, CIP-treated p50.
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determine the localization of Bcl-3, we constructed another
retrovirus vector with the HA epitope tag at the carboxyl
termini of Bcl-3 (MFG-bcl-3-HA). Immunofluorescent stain-
ing of cells transduced with this construct showed that
epitope-tagged Bcl-3 localized predominantly to the nucleus,
although some slight staining was observed in the cytoplasm
(Fig. 3A, panels 1 and 2).
To determine whether Bcl-3 could localize to the nucleus
in the presence of p50, we conducted double immunofluo-
rescence staining of cells after coinfection with viruses that
expressed HA-pSO (pZip-HA-p50) and wild-type Bcl-3
(MFG-bcl-3). We first confirmed by immunolocalization the
previous studies showing that p50 is localized constitutively
to the nucleus of cells (5, 18). For this experiment, NIH 3T3
cells were infected with a recombinant retrovirus expressing
an amino-terminal HA epitope-tagged p50 molecule (pZIP-
HA-p50). Two days after infection, cells were stained for
HA-specific expression, using a monoclonal anti-HA anti-
body. Cells expressing HA-p50 showed clear immunolocal-
ization of HA-p50 protein to the nucleus (Fig. 3A, panels 3
and 4). Cells were then coinfected with retroviruses express-
ing either HA-pSO or Bcl-3. When Bcl-3 was expressed by
itself in cells, it was present in the nucleus, as was observed
for epitope-tagged J3cl-3-HA (panel 5). When cells coex-
pressed HA-pSO and Bcl-3, specific staining for both mole-
cules was observed in the nucleus (compare panels S and 6).
To show that a nonspecific effect of the HA tag on one of the
two proteins does not lead to artifactual results, infections
were also carried out and imaged by using wild-type p50
(pZip-p50) and HA-Bcl-3 (MFG-bcl-3-HA). The results were
identical with use of either pairing (data not shown). This
finding is a strong indication that in vivo Bcl-3 plays some
role in the nucleus, in sharp contrast to the role of classically
defined IKB, which is proposed to maintain regulated cyto-
plasmic residence of NF-KB.
We examined whether Bcl-3 could influence the subcellu-
lar localization of a p50 protein mutant at its nuclear-
localizing signal (NLS) sequence. We first confirmed that the
p50-A&NLS protein localized primarily to the cytoplasm.
Infection of NIH 3T3 cells with the pZip-p50-ANLS-HA
retrovirus and immunofluorescence staining showed that, as
previously reported (5, 18), removal of the NLS results in a
localization of this mutant p50 to the cytoplasm (compare
p50 in Fig. 3A, panel 4, with p50-ANLS in Fig. 3B, panel 1),
although some slight staining is observed in the nucleus.
Surprisingly, coexpression of Bcl-3 and p50-ANLS-HA re-
sulted in the redistribution of much of the Bcl-3 to the
cytoplasm of cells (Fig. 3B, panels 2 and 3; compare Bcl-3
protein in cells coexpressing p50 and those not coexpressing
p50). Therefore, p50-ANLS seems capable of redirecting the
localization of Bcl-3, probably including a physical associa-
tion between p50 and Bcl-3 in cells. This finding suggests
that the subcellular location of p50 might influence the
localization of Bcl-3.
Because baculovirus-produced Bcl-3 is capable of actively
inhibiting the DNA binding of p50 in vitro, and the proteins
colocalize to the nucleus, we examined whether antibodies
directed against either Bcl-3 or p50 could immunoprecipitate
the other component from cell lysates. In cells transfected
with p50, antibodies to p50 immunoprecipitated a band of
-47-kDa apparent molecular mass that is the p50 product
(Fig. 4, lane 1). This 47-kDa band corresponds in size to the
p50-specific bands observed in Western blots of lysates of
these cells (not shown). Antibodies directed against Bcl-3
immunoprecipitated a pair of 52-kDa bands from bcl-3-
transfected lysates (lane 6). Again, these bands correspond
in size to Bcl-3-specific bands observed in Western blots of
lysates of these cells and to proteins observed by Western
blots of infected epitope-tagged Bcl-3 in NIH 3T3 cells (Fig.
2A). By Western blot and Coomassie blue stain analysis, the
apparent amount of p50 produced in transfected 293 cells is
in great excess over the amount of Bcl-3 produced (data not
shown). When p50 and bcl-3 were cotransfected, antibodies
to Bcl-3 coimmunoprecipitated p50 bands (lane 10). Antibod-
ies to p50 coprecipitated Bcl-3 bands (lane 9). The addition
of 500 ng of unlabeled Bcl-3 resulted in the specific blocking
of immunoprecipitated labeled Bcl-3 (lane 7) but resulted in
the coimmunoprecipitation of a level of free labeled p50 (lane
11) equivalent to that observed in lane 10. The ability to
precipitate labeled p50 with cold Bcl-3 protein is likely due to
excess production of transfected p50 and its association with
unlabeled Bcl-3 protein-antibody complex.
We also observed a 37-kDa band that immunoprecipitated
in transfected and untransfected 293 cells with use of the
anti-Bcl-3 antibody (Fig. 4, lanes 2, 6, 10, and 14). Kerr et al.
(22a) report that an induced 37-kDa band that they observe
in HeLa cells with use of anti-Bcl-3 polyclonal antibodies is
a probable proteolytic product of full-length Bcl-3 and might
correspond to IKB-, as revealed by their phosphopeptide
analysis. Since we do not observe any increase of this
37-kDa band in 293 cells after transfection of Bcl-3, it is
unlikely that full-length Bcl-3 is significantly processed to a
smaller 37-kDa form, and we believe that it is a cross-
reactive protein. Additionally, IKB-13 has been previously
shown to be a 45-kDa protein (45). Thus, Bcl-3 is likely to be
a novel protein with some similarities to the originally
defined IKB polypeptides but is clearly distinct from either
IKB-ax or IKB-13.
Bcl-3 mRNA is widely expressed. p50 is expressed consti-
tutively in many mammalian cells, including all tested hema-
topoietically derived cells (13). bcl-3 mRNA shows a simi-
larly broad expression pattern. bcl-3 mRNA is highly
expressed in the spleen and liver (Fig. 5). There was lower
expression in the heart, skeletal muscle, lung, kidney, and
testes, with no apparent expression in the brain. The appar-
ent size of bcl-3 mRNA is 2.8 kb, and there is only a single
resolvable species of poly(A)-containing mRNA. bcl-3 is
therefore also broadly expressed and, like other members of
the rel and IKB families (17, 37), can be transcriptionally
induced following stimuli that induce NF-KB (32).
DISCUSSION
We find that the baculovirus-produced Bcl-3 protein can
interact specifically with (P5O)2 and (p52)2 complexes and
inhibit their binding to the KB motif present in the enhancer
of the IgK gene. This inhibitory activity is modulated by the
phosphorylation state of the protein. When overexpressed,
Bcl-3 localizes by itself to the cell nucleus, and when it is
coexpressed with p50 in cells, the two simultaneously local-
ize to the nucleus and form a complex evident in nuclear
extracts. By contrast, IKB-a is a protein whose apparent
function is to regulate NF-KB localization in the cytoplasm
of cells. Thus, Bcl-3 is a new type of regulator of Rel-related
transcriptional activators.
Structurally, Bcl-3 protein has a distinct pattern of
ankyrin-related repeats that is also found in IKB-at, avian
pp4O, and IKB-,y (the C-terminal region of the p50 precursor,
p105). This pattern is different from that in other ankyrin
repeat-containing proteins such as Notch, SWI4, SW16,
ankyrin, or Glp-1 (30). Furthermore, there are seven ankyrin
repeats in Bcl-3 just as in IKB--y, making them structurally
VOL. 13, 1993
MOL. CELL. BIOL.3562 NOLAN ET AL.
A 1 2
4
6
3
CHARACTERIZATION OF Bcl-3 3563
B 1
2 3
FIG. 3. Localization of Bcl-3 to the nucleus alone and in the presence of p50. Cells were infected with epitope-tagged p50 and bcl-3
retroviruses and stained as described in Materials and Methods. (A) Colocalization of p50 and Bcl-3. Panels: 1, phase-contrast image of panel
2; 2, infection with bcl-3 (epitope-tagged) retrovirus and immunofluorescence stained with anti-HA-epitope monoclonal antibody; 3,
phase-contrast image of panel 4; 4, infection with 5'-HA epitope-tagged p50 retrovirus, immunolocalized with anti-HA epitope monoclonal
antibody; 5 and 6, coinfection of cells with pZip-HA-p50 and MFG-bcl-3 imaged with anti-Bcl-3 polyclonal antibody (panel 5) and anti-HA
(panel 6). (B) Evidence that a nuclear-localizing mutant of p50 can redirect Bcl-3 to the cytoplasm. Panels: 1, p50-ANLS-HA stained with
anti-HA; 2, pZIP-p50-ANLS-HA- and MFG-bcl-3-coinfected cells stained with anti-Bcl-3 (panel 2) and anti-HA (panel 3).
distinguishable from the five-repeat IKB-a family. Function-
ally, IKB--y and Bcl-3 are also most related because each is
focused on (P50)2 (19, 26), while IKB-a and IKB-1 are
focused on p65 and heterodimeric NF-KB. Bcl-3 is different
from IKB--y, however, in being nuclear and regulated by
phosphorylation. Furthermore, Bcl-3 under certain circum-
stances can be an activator of transcription (lla). There is an
as yet uncharacterized form of IKB called 1B that is also
regulated by phosphorylation but binds well to p65 and
c-Rel. (These authors consider this form of IKB to be related
to pp4O, although our protein sequence data clearly estab-
lished the homology of IKB-a and pp40 [9, 30].)
While this report was in preparation, Wulczyn et al. (43)
reported that bacterially produced Bcl-3 showed a prefer-
ence for inhibiting p50 rather than p65 binding to DNA, but
they found that the activities of Bcl-3 and IKB-a were
comparable against the p50:p65 heterodimer. This observa-
tion is in distinct contrast to our results. We found that Bcl-3
efficiently inhibited eukaryotically expressed p50 and p52
binding at concentrations that did not inhibit reconstituted
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FIG. 4. Physical association of Bcl-3 with p50 in cells. Lysates of
293 (ElA-transformed human embryonic kidney) cells transfected
with CDM-8-p5O (lanes 1 to 4), MFG-bcl-3 (lanes 5 to 8), or
MFG-bcl-3 plus CDM-8-p5O (lanes 9 to 12) and of control untrans-
fected cells (lanes 13 to 16) were immunoprecipitated with either
anti-pSO (lanes 1, 5, 9, and 13), anti-Bcl-3 (lanes 2, 6, 10, and 14),
anti-Bcl-3 plus 500 ng of cold Bcl-3 protein (lanes 3, 7, 11, and 15),
or normal rabbit polyclonal Ig (lanes 4, 8, 12, and 16). Sizes are
indicated in kilodaltons.
NF-KB p5O and p65 binding. They used bacterially produced
and therefore probably poorly phosphorylated protein. In
our experiments, bacterially and baculovirus-generated
Bcl-3 proteins have indistinguishable specificities. A more
critical difference is probably that their Bcl-3 protein was
truncated at both ends. Of a full-length 454-amino-acid Bcl-3
protein, these authors reported using a 289-amino-acid dele-
tion mutant that corresponded to primarily the ankyrin
domains from 94 to 383 amino acids, removing most of the
flanking region that potentially contain itnportant regulatory
domains. In addition, the proteins used by these authors
underwent denaturation-renaturation. Such truncation and
denaturation might have caused their protein to lose speci-
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FIG. 5. Evidence that bcl-3 mRNA is widely expressed. bcl-3
cDNA was radiolabeled and hybridized against a nitrocellulose filter
to which were bound poly(A)-enriched fractions of total RNA from
the indicated tissues. Sizes are indicated in kilobases.
ficity. Kerr and colleagues (22a) also report that Bcl-3 can
inhibit NF-KB at very high concentrations but did not
present titration of the levels of Bcl-3 in their report. In
addition, their Bcl-3 constructs consist of GST fusions that
might lead to results different from those presented here.
Finally, since we have recently observed (25a) that com-
plexes once thought to be NF-KB p5O:p65 are composed in
part of c-Rel, it is possible that the protein used by others is
not authentic NF-KB. Alternatively, a true difference might
exist between Bcl-3's ability to interact with reconstituted
p5O:p65 compared with NF-KB p5O:p65 derived from mam-
malian cells. We believe that the differences between our
data and those of others may lay with their use of truncated
or improperly modified Bcl-3. Franzoso et al. have recently
reported transcriptional inhibition results by transfection
that are in good agreement with our in vitro inhibitions (11).
Bcl-3 was capable of inhibiting the binding of p50 to Ig KB
sites and removing bound (P5O)2 protein from DNA. On
certain KB sites, Bcl-3 might therefore inhibit the binding of
p50 to DNA in a regulated manner. IKB also can actively
dissociate its target, NF-KB, from DNA (45), suggesting that
a general ability of IKB-like molecules might be to induce a
conformational change in appropriate Rel complexes that
catalyzes their dissociation from DNA. In these regards,
Franzoso et al. (11) have recently suggested that Bcl-3 can
inhibit the binding of p50 to DNA in cotransfections and
allow NF-KB to bind and mediate transcriptional activation.
Thus, Bcl-3 might act to remove p50 (a transcriptional
activator in its own right [12]) from certain KB sites to allow
the binding of repressors or activators. Interestingly, we
have observed that Bcl-3 does not inhibit the binding of p50
to H-2 KB sites (lla). The ability of Bcl-3 to inhibit (P5O)2
binding to certain sites is reminiscent of the site-dependent
transcriptional induction previously observed for p50 (12). In
that study, it was shown that p50 assumes a protease-
resistant structure on H-2 KB motifs but not upon Ig or beta
interferon KB motifs. With H-2 KB motifs placed upstream of
a minimal promoter, p50 was a strong in vitro transcriptional
activator, whereas it acted weakly as an activator on an Ig or
beta interferon KB site. Thus, in vivo, the possibility exists
that p50 bound to the H-2 motif acts as a constitutive
transcriptional inducer in a structural conformation that is
refractory to inhibition by Bcl-3.
Bcl-3 differs from IKB in it subcellular localization. Bcl-3
localizes to the nuclei of cells (Fig. 3C), even in the presence
of p50, and can physically associate in cells with p50. The
cellular association with p50 is supported by the striking
finding that a p50 mutant deleted for the NLS can redirect
Bcl-3 subcellular localization to the cytoplasm. Therefore,
although Bcl-3 has a capacity to intrinsically localize to the
nucleus by an unknown mechanism, the location of p50 can
dominate the localization of Bcl-3, perhaps by masking the
as yet undefined NLS of Bcl-3. This is in contrast to previous
models in which IKB regulates NF-KB activity by its seques-
tration in the cytoplasm, presumably by masking of the NLS
of p65 (4). Zabel and Baeuerle (45) have postulated that IKB
may have a role in the nucleus of cells as a result of the
ability of IKB to actively dissociate NF-KB bound to DNA in
vitro. Because baculovirus-produced Bcl-3 also actively
dissociates p50 bound to DNA (Fig. 1B, lanes 1 and 2), a role
of Bcl-3 in cells might be to sequester p50 in the nucleus in
a non-DNA-binding complex. It is also possible that certain
modified forms of Bcl-3 associate with p50 while p50 is
bound to DNA (lla). It might be relevant that Kang et al.
have recently reported that a deoxycholate-releasable factor
that inhibits the binding of p50 to DNA can be found in the
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nucleus of activated T-cell clones (21). This activity might
represent Bcl-3 or the other described specific inhibitor of
p50, IKB--y.
Interestingly, bcl-3 mRNA levels increase after stimuli
that activate NF-KB (32), suggesting that NF-KB can play a
direct role in the transcriptional induction of this mRNA.
This is similar to the increase in IKB-a mRNA levels in
monocytes after activation (17) and during the acute-phase
response in liver (38). Such synthesis might represent a
feedback mechanism to produce new Bcl-3 or IKB, replacing
that which has been modified or degraded after activation
(33a). We note that the promoter region of human bcl-3 (32)
contains three potential NF-KB-binding motifs. Two of these
motifs, (GGGACACCCC) and (GGGAAGTCCC), are KB
motifs that would be predicted to bind p5O homodimers or
NE-KB. Interestingly, both sites, when extended into 11
nucleotides by using flanking sequence, also share resem-
blance with the 11-bp KBF-1 site that binds p5O homodimers
in the Kb promoter (20). Therefore, it is possible that p5O
participates directly in the regulation of Bcl-3.
Bcl-3 and IKB-y are both directed at p5O homodimers,
contain seven ankyrin domains apiece, and share consider-
able homology (reference 30) and references therein). It is
possible that these two soluble inhibitors target p5O for
different regulatory reasons. Thus, the question arises as to
where the specificity resides in Bcl-3 and the CTR of p105
and IKB-a for their cognate Rel proteins and how this
specificity difference translates to functional differences.
Structure predictions of the four classes of inhibitory
ankyrin proteins (Bcl-3, IKB-a, pp4O, p105, and plOO)
strongly predict a helix-turn-helix-turn topology for the
ankyrin domain (30a). In this model, the relatively conserved
TPLH motif constitutes the turn just before the beginning of
the helix; helix-ending residues are found near the end of
each ankyrin motif. Thus, it is possible that the ankyrin
domains fold upon themselves in a series of helices. In
support of this view, another protein family, the snap-helix
proteins of the TPR family, are composed of repeated
35-amino-acid motifs that are predicted to form helix-turn
structure (16). Like the ankyrin motif, the TPR snap-helix
motif was originally identified in the cell division control
genes of Saccharomyces cerevisiae, and both were later
both found in similar settings such as transcription, protein-
protein association, and matrix structure. The TPR motif has
little apparent overall sequence homology to ankyrin do-
mains. However, ankyrin motifs (30) contain groups of
conserved small side chain residues (alanines and glycines)
as well as conserved bulky hydrophobic residues (leucines
and histidines) at appropriate spacing that might well serve
as knobs and holes of helix-associating domains, analogous
to the model proposed for the TPR structure (16). Examina-
tion of these structural and functional similarities of ankyrin
and TPR motifs might help in an understanding of how
proteins containing such internally repeated domains carry
out their heterogeneous functions.
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